Potential roles of NCAM/PSA-NCAM proteins in depression and the mechanism of action of antidepressant drugs

被引：0
作者：
Wêdzony K. [1 ]
Chocyk A. [1 ]
Maækowiak M. [1 ]
机构：
[1] Laboratory of Pharmacology and Brain Biostructure, Department of Pharmacologcy, Institute of Pharmacology, PL 31-343 Kraków
来源：
Pharmacological Reports | 2013年 / 65卷 / 6期
关键词：
Antidepressant drugs; Depression; NCAM; PSA-NCAM;
D O I：
10.1016/S1734-1140(13)71507-X
中图分类号：
学科分类号：
摘要：
Recently, it has been proposed that abnormalities in neuronal structural plasticity may underlie the pathogenesis of major depression, resulting in changes in the volume of specific brain regions, including the hippocampus (HIP), the prefrontal cortex (PC), and the amygdala (AMY), as well as the morphology of individual neurons in these brain regions. In the present survey, we compile the data regarding the involvement of the neural cell adhesion molecule (NCAM) protein and its polysialylated form (PSA-NCAM) in the pathogenesis of depression and the mechanism of action of antidepressant drugs (ADDs). Elevated expression of PSA-NCAM may reflect neuroplastic changes, whereas decreased expression implies a rigidification of neuronal morphology and an impedance of dynamic changes in synaptic structure. Special emphasis is placed on the clinical data, genetic models, and the effects of ADDs on NCAM/PSA-NCAM expression in the brain regions in which these proteins are constitutively expressed and neurogenesis is not a major factor; this emphasis is necessary to prevent cell proliferation and neurogenesis from obscuring the issue of brain plasticity. Copyright © 2013 by Institute of Pharmacology Polish Academy of Sciences.
引用
收藏
页码：1471 / 1478
页数：7
相关论文
共 45 条
[1]  
Aonurm-Helm A., Jurgenson M., Zharkovsky T., Sonn K., Berezin V., Bock E., Zharkovsky A., Depression-like behaviour in neural cell adhesion molecule (ncam)-deficient mice and its reversal by an ncam-derived peptide, fgl, Eur J Neurosci, 28, pp. 1618-1628, (2008)
[2]  
Bessa J.M., Morais M., Marques F., Pinto L., Palha J.A., Almeida O.F., Sousa N., Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens, Transl Psychiatry, 3, pp. 1-7, (2013)
[3]  
Bora E., Fornito A., Pantelis C., Yucel M., Gray matter abnormalities in major depressive disorder: A metaanalysis of voxel based morphometry studies, J Affect Disord, 138, pp. 9-18, (2012)
[4]  
Calandreau L., Marquez C., Bisaz R., Fantin M., Sandi C., Differential impact of polysialyltransferase st8siaii and st8siaiv knockout on social interaction and aggression, Genes Brain Behav, 9, pp. 958-967, (2010)
[5]  
Chocyk A., Dudys D., Przyborowska A., Maaekowiak M., Wedzony K., Impact of maternal separation on neural cell adhesion molecules expression in dopaminergic brain regions of juvenile, adolescent and adult rats, Pharmacol Rep, 62, pp. 1218-1224, (2010)
[6]  
Choi M.R., Oh D.H., Kim S.H., Jung K.H., Das N.D., Chai Y.G., Fluoxetine increases the expression of ncam140 and pcreb in rat c6 glioma cells, Psychiatry Investig, 9, pp. 180-186, (2012)
[7]  
Conboy L., Tanrikut C., Zoladz P.R., Campbell A.M., Park C.R., Gabriel C., Mocaer E., Et al., The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (ncam) expression in the hippocampus of rats, Int J Neuropsychopharmacol, 12, pp. 329-341, (2009)
[8]  
Djordjevic A., Djordjevic J., Elakovic I., Adzic M., Matic G., Radojcic M.B., Effects of fluoxetine on plasticity and apoptosis evoked by chronic stress in rat prefrontal cortex, Eur J Pharmacol, 693, pp. 37-44, (2012)
[9]  
Djordjevic A., Djordjevic J., Elakovic I., Adzic M., Matic G., Radojcic M.B., Fluoxetine affects hippocampal plasticity, apoptosis and depressive-like behavior of chronically isolated rats, Prog Neuropsychopharmacol Biol Psychiatry, 36, pp. 92-100, (2012)
[10]  
Du M.Y., Wu Q.Z., Yue Q., Li J., Liao Y., Kuang W.H., Huang X.Q., Et al., Voxelwise meta-analysis of gray matter reduction in major depressive disorder, Prog Neuropsychopharmacol Biol Psychiatry, 36, pp. 11-16, (2012)
12345